Literature DB >> 16855154

Are glucocorticoids DMARDs?

Johannes W J Bijlsma1, Jos N Hoes, Amalia A Van Everdingen, Suzan M M Verstappen, Johannes W G Jacobs.   

Abstract

Disease modifying antirheumatic drugs (DMARDs) are drugs used in rheumatoid arthritis (RA) to control the disease and to limit joint damage and improve long-term outcome. The last decade evidence has accumulated that suggests that low dosages of glucocorticoids are indeed able to control the disease and limit the destruction. This role is especially present in early disease and in combination with other drugs. The evidence is carefully evaluated and discussed. The ultimate conclusion is that indeed glucocorticoids are DMARDs and are especially useful in early RA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16855154     DOI: 10.1196/annals.1351.025

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

1.  Effects of long-term corticosteroid usage on functional disability in patients with early rheumatoid arthritis, regardless of controlled disease activity.

Authors:  Eiichi Tanaka; Ajitha Mannalithara; Eisuke Inoue; Noriko Iikuni; Atsuo Taniguchi; Shigeki Momohara; Gurkirpal Singh; Hisashi Yamanaka
Journal:  Rheumatol Int       Date:  2010-12-16       Impact factor: 2.631

2.  Prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  Jeffrey R Curtis; Kenneth G Saag
Journal:  Curr Osteoporos Rep       Date:  2007-03       Impact factor: 5.096

3.  [Disease-modifying effects of glucocorticoids in rheumatoid arthritis].

Authors:  F Buttgereit; G Burmester; J W Bijlsma
Journal:  Z Rheumatol       Date:  2007-10       Impact factor: 1.372

Review 4.  Glucocorticoids in rheumatoid arthritis.

Authors:  Roberto Caporali; Monica Todoerti; Garifallia Sakellariou; Carlomaurizio Montecucco
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

5.  Time trends in glucocorticoid use in rheumatoid arthritis: results from a population-based inception cohort, 1980-1994 versus 1995-2007.

Authors:  Ashima Makol; John M Davis; Cynthia S Crowson; Terry M Therneau; Sherine E Gabriel; Eric L Matteson
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-10       Impact factor: 4.794

6.  Pattern of drugs use and association with anti-mutated citrullinated vimentin antibody in rheumatoid arthritis.

Authors:  Mohammad-Ayman A Safi; Omar A Fathaldin
Journal:  Saudi Med J       Date:  2015-03       Impact factor: 1.484

Review 7.  Insights into endocrine-immunological disturbances in autoimmunity and their impact on treatment.

Authors:  Maurizio Cutolo; Rainer H Straub
Journal:  Arthritis Res Ther       Date:  2009-04-06       Impact factor: 5.156

8.  Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study.

Authors:  Carlomaurizio Montecucco; Monica Todoerti; Garifallia Sakellariou; Carlo Alberto Scirè; Roberto Caporali
Journal:  Arthritis Res Ther       Date:  2012-05-14       Impact factor: 5.156

Review 9.  Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility.

Authors:  M F Bakker; J W G Jacobs; S M M Verstappen; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 27.973

10.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maya Buch; Gerd Burmester; Maxime Dougados; Paul Emery; Cécile Gaujoux-Viala; Laure Gossec; Jackie Nam; Sofia Ramiro; Kevin Winthrop; Maarten de Wit; Daniel Aletaha; Neil Betteridge; Johannes W J Bijlsma; Maarten Boers; Frank Buttgereit; Bernard Combe; Maurizio Cutolo; Nemanja Damjanov; Johanna M W Hazes; Marios Kouloumas; Tore K Kvien; Xavier Mariette; Karel Pavelka; Piet L C M van Riel; Andrea Rubbert-Roth; Marieke Scholte-Voshaar; David L Scott; Tuulikki Sokka-Isler; John B Wong; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-10-25       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.